

Franco Dammacco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8210044/publications.pdf>

Version: 2024-02-01

292
papers

16,671
citations

11908

72
h-index

22488

117
g-index

295
all docs

295
docs citations

295
times ranked

16911
citing authors

#	ARTICLE	IF	CITATIONS
1	The wide spectrum of cryoglobulinemic vasculitis and an overview of therapeutic advancements. <i>Clinical and Experimental Medicine</i> , 2023, 23, 255-272.	1.9	11
2	Ocular Manifestations in an Italian Cohort of Patients with Takayasu Arteritis. <i>Ocular Immunology and Inflammation</i> , 2023, 31, 945-954.	1.0	2
3	Highlights in clinical medicine—Giant cell arteritis, polymyalgia rheumatica and Takayasu’s arteritis: pathogenic links and therapeutic implications. <i>Clinical and Experimental Medicine</i> , 2022, 22, 509-518.	1.9	1
4	Natural and iatrogenic ocular manifestations of rheumatoid arthritis: a systematic review. <i>International Ophthalmology</i> , 2022, 42, 689-711.	0.6	9
5	Takayasu arteritis: a cohort of Italian patients and recent pathogenetic and therapeutic advances. <i>Clinical and Experimental Medicine</i> , 2021, 21, 49-62.	1.9	11
6	The Spectrum of Ocular Manifestations in Patients with Waldenström’s Macroglobulinemia. <i>Ocular Immunology and Inflammation</i> , 2021, , 1-10.	1.0	5
7	Early echocardiographic detection of left ventricular diastolic dysfunction in patients with systemic lupus erythematosus asymptomatic for cardiovascular disease. <i>Clinical and Experimental Medicine</i> , 2020, 20, 11-19.	1.9	24
8	Amyloidosis and Ocular Involvement: an Overview. <i>Seminars in Ophthalmology</i> , 2020, 35, 7-26.	0.8	22
9	Ocular sarcoidosis: clinical experience and recent pathogenetic and therapeutic advancements. <i>International Ophthalmology</i> , 2020, 40, 3453-3467.	0.6	20
10	<p>Giant Cell Arteritis: The Experience of Two Collaborative Referral Centers and an Overview of Disease Pathogenesis and Therapeutic Advancements</p>. <i>Clinical Ophthalmology</i> , 2020, Volume 14, 775-793.	0.9	13
11	Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial. <i>Journal of Hematology and Oncology</i> , 2019, 12, 4.	6.9	27
12	CD5/CD20 expression on circulating B cells in HCV-related chronic hepatitis and mixed cryoglobulinemia. <i>European Journal of Internal Medicine</i> , 2019, 66, 48-56.	1.0	2
13	Pemphigus and mucous membrane pemphigoid: An update from diagnosis to therapy. <i>Autoimmunity Reviews</i> , 2019, 18, 349-358.	2.5	81
14	Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma—Enhanced Angiogenesis: A Novel Therapeutic Target?. <i>Neoplasia</i> , 2019, 21, 93-105.	2.3	28
15	From the Double Helix to Oncogenomics and Precision Cancer Medicine. , 2019, , 3-16.		0
16	Cancer Stem Cells in Multiple Myeloma and the Development of Novel Therapeutic Strategies. , 2019, , 121-137.		2
17	Bone Metastases from Solid Tumors. , 2019, , 141-163.		2
18	Gene Fusion in NSCLC. , 2019, , 443-464.		1

#	ARTICLE	IF	CITATIONS
19	Clinical practice: hepatitis C virus infection, cryoglobulinemia and cryoglobulinemic vasculitis. <i>Clinical and Experimental Medicine</i> , 2019, 19, 1-21.	1.9	39
20	Bone marrow endothelial cells sustain a tumor-specific CD8 ⁺ T cell subset with suppressive function in myeloma patients. <i>Onc Immunology</i> , 2019, 8, e1486949.	2.1	58
21	Subcutaneous immunoglobulins in patients with multiple myeloma and secondary hypogammaglobulinemia: a randomized trial. <i>Clinical Immunology</i> , 2018, 191, 110-115.	1.4	62
22	A multiple myeloma that progressed as type I cryoglobulinemia with skin ulcers and foot necrosis. <i>Medicine (United States)</i> , 2018, 97, e12355.	0.4	10
23	Belimumab restores Treg/Th17 balance in patients with refractory systemic lupus erythematosus. <i>Lupus</i> , 2018, 27, 1926-1935.	0.8	14
24	Common Variable Immunodeficiency and Gastric Malignancies. <i>International Journal of Molecular Sciences</i> , 2018, 19, 451.	1.8	38
25	Ocular Involvement in Systemic Lupus Erythematosus: The Experience of Two Tertiary Referral Centers. <i>Ocular Immunology and Inflammation</i> , 2018, 26, 1154-1165.	1.0	28
26	Cancer treatment and the KIR*HLA system: an overview. <i>Clinical and Experimental Medicine</i> , 2017, 17, 419-429.	1.9	21
27	Direct-acting antiviral agents in the therapy of hepatitis C virus-related mixed cryoglobulinaemia: a single-centre experience. <i>Arthritis Research and Therapy</i> , 2017, 19, 74.	1.6	44
28	HEAVY-CHAIN DISEASES AND MYELOMA-ASSOCIATED FANCONI SYNDROME: AN UPDATE. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018011.	0.5	10
29	Functional and Biological Role of Endothelial Precursor Cells in Tumour Progression: A New Potential Therapeutic Target in Haematological Malignancies. <i>Stem Cells International</i> , 2016, 2016, 1-11.	1.2	25
30	Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma. <i>Oncotarget</i> , 2016, 7, 29677-29688.	0.8	13
31	Autoimmune Hepatitis: Factors Involved in Initiation and Methods of Diagnosis and Treatment. <i>Critical Reviews in Immunology</i> , 2016, 36, 407-428.	1.0	3
32	The expanding spectrum of HCV-related cryoglobulinemic vasculitis: a narrative review. <i>Clinical and Experimental Medicine</i> , 2016, 16, 233-242.	1.9	30
33	Myeloma bone and extra-medullary disease: Role of PET/CT and other whole-body imaging techniques. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 101, 169-183.	2.0	23
34	Halting pro-survival autophagy by TGF β 2 inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. <i>Leukemia</i> , 2016, 30, 640-648.	3.3	69
35	HCV-Related Cryoglobulinemic Vasculitis: An Overview. , 2016, , 333-344.		0
36	Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. <i>Blood</i> , 2015, 126, 1443-1451.	0.6	78

#	ARTICLE	IF	CITATIONS
37	Myeloma cells act as tolerogenic antigen-presenting cells and induce regulatory T cells <i>in vitro</i> . <i>European Journal of Haematology</i> , 2015, 95, 65-74.	1.1	17
38	Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. <i>World Journal of Gastroenterology</i> , 2015, 21, 11974.	1.4	80
39	Erdheim-Chester disease: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 1-11.	2.0	153
40	Thymic stromal lymphopoietin in hepatitis C virus-related cryoglobulinemic vasculitis: gene expression level and protein distribution. <i>Arthritis Research and Therapy</i> , 2015, 17, 62.	1.6	8
41	Activation-induced cytidine deaminase in B cells of hepatitis C virus-related cryoglobulinemic vasculitis. <i>Clinical and Experimental Immunology</i> , 2015, 182, 323-331.	1.1	1
42	18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders. <i>Clinical and Experimental Medicine</i> , 2015, 15, 1-18.	1.9	60
43	Filgrastim, lenograstim and pegfilgrastim in the mobilization of peripheral blood progenitor cells in patients with lymphoproliferative malignancies. <i>Clinical and Experimental Medicine</i> , 2015, 15, 145-150.	1.9	26
44	The immune escape in melanoma: role of the impaired dendritic cell function. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 1395-1404.	1.3	56
45	Assessment of total hepatitis C virus (HCV) core protein in HCV-related mixed cryoglobulinemia. <i>Arthritis Research and Therapy</i> , 2014, 16, R73.	1.6	6
46	HIF-1 α of Bone Marrow Endothelial Cells Implies Relapse and Drug Resistance in Patients with Multiple Myeloma and May Act as a Therapeutic Target. <i>Clinical Cancer Research</i> , 2014, 20, 847-858.	3.2	54
47	Dendritic cell maturation in HCV infection: Altered regulation of MHC class I antigen processing-presenting machinery. <i>Journal of Hepatology</i> , 2014, 61, 242-251.	1.8	14
48	Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: <i>in vitro</i> and <i>in vivo</i> studies. <i>Leukemia</i> , 2014, 28, 904-916.	3.3	88
49	Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. <i>Journal of Infection</i> , 2014, 68, 1-20.	1.7	69
50	Interleukin 28B Gene Polymorphisms in Hepatitis C Virus-related Cryoglobulinemic Vasculitis. <i>Journal of Rheumatology</i> , 2014, 41, 91-98.	1.0	11
51	Goodpasture's disease: A report of ten cases and a review of the literature. <i>Autoimmunity Reviews</i> , 2013, 12, 1101-1108.	2.5	55
52	Immature dendritic cells in multiple myeloma are prone to osteoclast-like differentiation through interleukin-17 stimulation. <i>British Journal of Haematology</i> , 2013, 161, 821-831.	1.2	42
53	Cancer-related coagulopathy (Trousseau's syndrome): review of the literature and experience of a single center of internal medicine. <i>Clinical and Experimental Medicine</i> , 2013, 13, 85-97.	1.9	63
54	Therapy for Hepatitis C Virus-Related Cryoglobulinemic Vasculitis. <i>New England Journal of Medicine</i> , 2013, 369, 1035-1045.	13.9	159

#	ARTICLE	IF	CITATIONS
55	Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe. <i>Cellular Signalling</i> , 2013, 25, 1108-1117.	1.7	21
56	Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients. <i>Journal of Pathology</i> , 2013, 229, 87-98.	2.1	34
57	<i>H. pylori</i> infection and gastric cancer: State of the art. <i>International Journal of Oncology</i> , 2013, 42, 5-18.	1.4	178
58	MHC Class I Antigen Processing and Presenting Machinery: Organization, Function, and Defects in Tumor Cells. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1172-1187.	3.0	457
59	Neutropenia and G-CSF in lymphoproliferative diseases. <i>Hematology</i> , 2013, 18, 131-137.	0.7	7
60	Precancerous colorectal lesions. <i>International Journal of Oncology</i> , 2013, 43, 973-984.	1.4	92
61	Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2013, 15, R72.	1.6	7
62	Impact of Cryoglobulinemic Syndrome on the Outcome of Chronic Hepatitis C Virus Infection. <i>Medicine (United States)</i> , 2013, 92, 245-256.	0.4	40
63	A retrospective study of skeletal and disease-free survival benefits of zoledronic acid therapy in patients with multiple myeloma treated with novel agents. <i>International Journal of Clinical and Experimental Medicine</i> , 2013, 6, 30-8.	1.3	9
64	Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial. <i>Oncologist</i> , 2012, 17, 359-366.	1.9	142
65	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma. <i>Hematology</i> , 2012, 17, 23-27.	0.7	18
66	In Reply. <i>Oncologist</i> , 2012, 17, e24-e25.	1.9	0
67	Novel strategies in the treatment of castration-resistant prostate cancer (Review). <i>International Journal of Oncology</i> , 2012, 40, 1313-20.	1.4	19
68	High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk non-Hodgkin lymphoma. <i>Clinical and Experimental Medicine</i> , 2012, 12, 165-171.	1.9	15
69	Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets. <i>Oncogene</i> , 2012, 31, 2258-2269.	2.6	31
70	Barrett's esophagus and esophageal cancer: An overview. <i>International Journal of Oncology</i> , 2012, 41, 414-424.	1.4	58
71	Therapeutic approaches to myeloma bone disease: An evolving story. <i>Cancer Treatment Reviews</i> , 2012, 38, 787-797.	3.4	25
72	Clinical and experimental medicine: innovation and continuity. <i>Clinical and Experimental Medicine</i> , 2012, 12, 1-2.	1.9	0

#	ARTICLE	IF	CITATIONS
73	Lenalidomide in multiple myeloma: current experimental and clinical data. <i>European Journal of Haematology</i> , 2012, 88, 279-291.	1.1	14
74	<i>In vitro</i> anti-myeloma activity of TRAIL-expressing adipose-derived mesenchymal stem cells. <i>British Journal of Haematology</i> , 2012, 157, 586-598.	1.2	46
75	Antiviral Therapy in HCV-Positive Non-Hodgkin's Lymphoma: Pathogenetic Implications. , 2012, , 325-334.		0
76	Role of B-Cell-Attracting Chemokine-1 in HCV-Related Cryoglobulinemic Vasculitis. , 2012, , 127-135.		0
77	The Pivotal Role of C1qR in Mixed Cryoglobulinemia. , 2012, , 91-96.		0
78	PIRR Therapy in HCV-Related Mixed Cryoglobulinemia. , 2012, , 315-323.		0
79	The Higher Prevalence of B-Cell Non-Hodgkin's Lymphoma in HCV-Positive Patients with and Without Cryoglobulinemia. , 2012, , 267-272.		0
80	Dendritic Cells and Malignant Plasma Cells: An Alliance in Multiple Myeloma Tumor Progression?. <i>Oncologist</i> , 2011, 16, 1040-1048.	1.9	38
81	Antibody Vh Repertoire Differences between Resolving and Chronically Evolving Hepatitis C Virus Infections. <i>PLoS ONE</i> , 2011, 6, e25606.	1.1	31
82	Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 87-99.	2.0	12
83	Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation <i>in vitro</i> . <i>Experimental Hematology</i> , 2011, 39, 773-783.e1.	0.2	33
84	Autoantibodies to intracellular antigens: Generation and pathogenetic role. <i>Autoimmunity Reviews</i> , 2011, 10, 503-508.	2.5	66
85	Extra-articular manifestations of rheumatoid arthritis: An update. <i>Autoimmunity Reviews</i> , 2011, 11, 123-131.	2.5	151
86	Mesenchymal Stem Cells: A New Promise in Anticancer Therapy. <i>Stem Cells and Development</i> , 2011, 20, 1-10.	1.1	47
87	Cyclosporin-A Efficacy in Chronic Idiopathic Urticaria. <i>International Journal of Immunopathology and Pharmacology</i> , 2011, 24, 195-200.	1.0	19
88	⁹⁰ Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma. <i>Journal of Nuclear Medicine</i> , 2011, 52, 891-895.	2.8	5
89	Lenalidomide Restrains Motility and Overangiogenic Potential of Bone Marrow Endothelial Cells in Patients with Active Multiple Myeloma. <i>Clinical Cancer Research</i> , 2011, 17, 1935-1946.	3.2	75
90	Cell Fusion and Hyperactive Osteoclastogenesis in Multiple Myeloma. <i>Advances in Experimental Medicine and Biology</i> , 2011, 714, 113-128.	0.8	15

#	ARTICLE	IF	CITATIONS
91	Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. <i>Blood</i> , 2010, 115, 1185-1193.	0.6	66
92	Pegylated interferon- α , ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study. <i>Blood</i> , 2010, 116, 343-353.	0.6	236
93	The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXO3). <i>Clinical Immunology</i> , 2010, 137, 60-73.	1.4	10
94	Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide. <i>Leukemia Research</i> , 2010, 34, 243-249.	0.4	27
95	CD20-depleting therapy in autoimmune diseases: from basic research to the clinic. <i>Journal of Internal Medicine</i> , 2010, 267, 260-277.	2.7	78
96	Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. <i>Bone Marrow Transplantation</i> , 2010, 45, 277-281.	1.3	26
97	Targeted Therapies in Cancer. <i>BioDrugs</i> , 2010, 24, 77-88.	2.2	36
98	Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. <i>European Journal of Cancer</i> , 2010, 46, 420-429.	1.3	65
99	Managing myelodysplastic symptoms in elderly patients. <i>Clinical Interventions in Aging</i> , 2009, 4, 413.	1.3	40
100	Umbilical Cord Mesenchymal Stem Cells: Role of Regulatory Genes in Their Differentiation to Osteoblasts. <i>Stem Cells and Development</i> , 2009, 18, 1211-1220.	1.1	41
101	Bone-Resorbing Cells in Multiple Myeloma: Osteoclasts, Myeloma Cell Polykaryons, or Both?. <i>Oncologist</i> , 2009, 14, 264-275.	1.9	26
102	Oversecretion of Cytokines and Chemokines in Lupus Nephritis Is Regulated by Intraparenchymal Dendritic Cells. <i>Annals of the New York Academy of Sciences</i> , 2009, 1173, 449-457.	1.8	29
103	Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2009, 15, 5369-5378.	3.2	91
104	Two Structurally Different Rituximab-Specific CD20 Mimotope Peptides Reveal That Rituximab Recognizes Two Different CD20-Associated Epitopes. <i>Journal of Immunology</i> , 2009, 182, 416-423.	0.4	27
105	α 3 Integrin Subunit Mediates the Bone-Resorbing Function Exerted by Cultured Myeloma Plasma Cells. <i>Cancer Research</i> , 2009, 69, 6738-6746.	0.4	32
106	Role of the Receptor for the Globular Domain of C1q Protein in the Pathogenesis of Hepatitis C Virus-Related Cryoglobulin Vascular Damage. <i>Journal of Immunology</i> , 2009, 183, 6013-6020.	0.4	67
107	Biological functions and therapeutic use of erythropoiesis-stimulating agents: perplexities and perspectives. <i>British Journal of Haematology</i> , 2009, 146, 127-141.	1.2	20
108	Staging multiple myeloma patients with active disease using serum levels of α 2m-free HLA class I heavy chain together with IgM or platelet count. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 42, 71-76.	0.6	8

#	ARTICLE	IF	CITATIONS
109	Functional expression of the calcitonin receptor by human T and B cells. <i>Human Immunology</i> , 2009, 70, 678-685.	1.2	9
110	Role of Active Drug Transporters in Refractory Multiple Myeloma. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 218-224.	1.0	18
111	Biosimilars and safety issues. <i>Leukemia and Lymphoma</i> , 2009, 50, 656-658.	0.6	3
112	Genes and Proteins of Myeloma Endothelial Cells to Search Specific Targets of the Tumor Vasculature. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, S28-S29.	1.4	0
113	MicroRNAs to know in Waldenström macroglobulinemia. <i>Blood</i> , 2009, 113, 4133-4134.	0.6	1
114	Modulation of the Fc γ receptors induced by anti-Ro and anti-La autoantibodies: observations in salivary gland cells. <i>Rheumatology International</i> , 2008, 28, 943-948.	1.5	11
115	Long-term survival in multiple myeloma: a single-center experience. <i>Clinical and Experimental Medicine</i> , 2008, 8, 133-139.	1.9	6
116	Serum levels of angiogenic cytokines decrease after radiotherapy in non-Hodgkin lymphomas. <i>Clinical and Experimental Medicine</i> , 2008, 8, 141-145.	1.9	18
117	Glomerular accumulation of plasmacytoid dendritic cells in active lupus nephritis: Role of interleukin-18. <i>Arthritis and Rheumatism</i> , 2008, 58, 251-262.	6.7	207
118	ESAs not the culprit: More studies required. <i>American Journal of Hematology</i> , 2008, 83, 880-880.	2.0	4
119	Expression and function of the calcitonin receptor by myeloma cells in their osteoclast-like activity in vitro. <i>Leukemia Research</i> , 2008, 32, 611-623.	0.4	23
120	Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. <i>Oncogene</i> , 2008, 27, 663-674.	2.6	129
121	Antibodies to hepatitis C virus in essential mixed cryoglobulinaemia. <i>Clinical and Experimental Immunology</i> , 2008, 87, 352-356.	1.1	117
122	Pathogenic anti-DNA idiotype-reactive IgG in intravenous immunoglobulin preparations. <i>Clinical and Experimental Immunology</i> , 2008, 97, 19-25.	1.1	29
123	Soluble CD4 antigen reactivity in intravenous immunoglobulin preparations: is it specific?. <i>Clinical and Experimental Immunology</i> , 2008, 99, 16-20.	1.1	10
124	Delayed complete remission in a patient with multiple myeloma. <i>European Journal of Clinical Investigation</i> , 2008, 38, 966-968.	1.7	1
125	Endothelial Differentiation of Hematopoietic Stem and Progenitor Cells from Patients with Multiple Myeloma. <i>Clinical Cancer Research</i> , 2008, 14, 1678-1685.	3.2	44
126	Resveratrol Exerts Antiproliferative Activity and Induces Apoptosis in Waldenström's Macroglobulinemia. <i>Clinical Cancer Research</i> , 2008, 14, 1849-1858.	3.2	75

#	ARTICLE	IF	CITATIONS
127	Negative Regulation of the Osteoblast Function in Multiple Myeloma through the Repressor Gene E4BP4 Activated by Malignant Plasma Cells. <i>Clinical Cancer Research</i> , 2008, 14, 6081-6091.	3.2	32
128	Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia. <i>Current Medicinal Chemistry</i> , 2008, 15, 117-126.	1.2	6
129	Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. <i>Blood</i> , 2008, 112, 1620-1627.	0.6	56
130	Validation of PDGFR β and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. <i>Blood</i> , 2008, 112, 1346-1356.	0.6	99
131	Hepatitis C virus productive infection in mononuclear cells from patients with cryoglobulinaemia. <i>Clinical and Experimental Immunology</i> , 2007, 147, 241-248.	1.1	42
132	Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. <i>Leukemia and Lymphoma</i> , 2007, 48, 923-930.	0.6	9
133	Identification of an Antigenic and Immunogenic Motif Expressed by Two 7-Mer Rituximab-Specific Cyclic Peptide Mimotopes: Implication for Peptide-Based Active Immunotherapy. <i>Journal of Immunology</i> , 2007, 179, 7967-7974.	0.4	23
134	Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3256-3262.	1.9	74
135	Bone Marrow of Persistently Hepatitis C Virus-Infected Individuals Accumulates Memory CD8+ T Cells Specific for Current and Historical Viral Antigens: A Study in Patients with Benign Hematological Disorders. <i>Journal of Immunology</i> , 2007, 179, 5387-5398.	0.4	14
136	Mixed cryoglobulinemia: a model of virus-related disease in internal medicine. <i>Digestive and Liver Disease</i> , 2007, 39, S8-S12.	0.4	13
137	Myeloma bone disease: Pathogenetic mechanisms and clinical assessment. <i>Leukemia Research</i> , 2007, 31, 129-138.	0.4	44
138	Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic <i>in situ</i> hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. <i>Clinical and Experimental Immunology</i> , 2007, 103, 414-422.	1.1	101
139	Erythropoietin/erythropoietin-receptor system is involved in angiogenesis in human hepatocellular carcinoma. <i>Histopathology</i> , 2007, 50, 591-596.	1.6	57
140	Increased IL-18 Production by Dendritic Cells in Active Inflammatory Myopathies. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 184-192.	1.8	26
141	Role of the HLA Class II: HCV-Related Disorders. <i>Annals of the New York Academy of Sciences</i> , 2007, 1107, 308-318.	1.8	19
142	Dasatinib Inhibits Multiple Myeloma Growth by Blocking PDGF-R β and c-Src Activity in Patient-Derived Tumor and Endothelial Cells. <i>Blood</i> , 2007, 110, 550-550.	0.6	2
143	Resveratrol Exerts Antiproliferative Effect and Induces Apoptosis in Waldenstrom's Macroglobulinemia. <i>Blood</i> , 2007, 110, 1383-1383.	0.6	2
144	In-vitro functional phenotypes of plasma cell lines from patients with multiple myeloma. <i>Leukemia and Lymphoma</i> , 2006, 47, 1921-1931.	0.6	11

#	ARTICLE	IF	CITATIONS
145	Angiogenesis and anti-angiogenesis in hepatocellular carcinoma. <i>Cancer Treatment Reviews</i> , 2006, 32, 437-444.	3.4	77
146	Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. <i>Blood</i> , 2006, 107, 1070-1077.	0.6	87
147	Loss of inhibitory semaphorin 3A (SEMA3A) autocrine loops in bone marrow endothelial cells of patients with multiple myeloma. <i>Blood</i> , 2006, 108, 1661-1667.	0.6	79
148	Virological analysis and phenotypic characterization of peripheral blood lymphocytes of hepatitis C virus-infected patients with and without mixed cryoglobulinaemia. <i>Clinical and Experimental Immunology</i> , 2006, 143, 288-296.	1.1	37
149	HCV-NS3 and IgG-Fc crossreactive IgM in patients with type II mixed cryoglobulinemia and B-cell clonal proliferations. <i>Leukemia</i> , 2006, 20, 1145-1154.	3.3	72
150	Reply:. <i>Hepatology</i> , 2006, 43, 1167-1168.	3.6	2
151	Bortezomib as an Antitumor Agent. <i>Current Pharmaceutical Biotechnology</i> , 2006, 7, 441-448.	0.9	75
152	Antibody Production and In Vitro Behavior of CD27-Defined B-Cell Subsets: Persistent Hepatitis C Virus Infection Changes the Rules. <i>Journal of Virology</i> , 2006, 80, 3923-3934.	1.5	69
153	Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial Cells. <i>Cancer Research</i> , 2006, 66, 184-191.	0.4	266
154	CD20 Mimicry by a mAb Rituximab-Specific Linear Peptide: A Potential Tool for Active Immunotherapy of Autoimmune Diseases. <i>Annals of the New York Academy of Sciences</i> , 2005, 1051, 672-683.	1.8	15
155	Functional osteoclast-like transformation of cultured human myeloma cell lines. <i>British Journal of Haematology</i> , 2005, 130, 926-938.	1.2	39
156	Hepatitis C virus RNA and core protein in kidney glomerular and tubular structures isolated with laser capture microdissection. <i>Clinical and Experimental Immunology</i> , 2005, 140, 498-506.	1.1	92
157	CD20: A target antigen for immunotherapy of autoimmune diseases. <i>Autoimmunity Reviews</i> , 2005, 4, 526-531.	2.5	71
158	HCV-associated B cell clonalities in the liver do not carry the t(14;18) chromosomal translocation. <i>Hepatology</i> , 2005, 42, 1019-1027.	3.6	25
159	Thalidomide Downregulates Angiogenic Genes in Bone Marrow Endothelial Cells of Patients With Active Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2005, 23, 5334-5346.	0.8	125
160	Statins activate the mitochondrial pathway of apoptosis in human lymphoblasts and myeloma cells. <i>Carcinogenesis</i> , 2005, 26, 883-891.	1.3	230
161	Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. <i>Lancet Infectious Diseases</i> , The, 2005, 5, 227-236.	4.6	227
162	A VEGF-dependent autocrine loop mediates proliferation and capillarogenesis in bone marrow endothelial cells of patients with multiple myeloma. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1438-1445.	1.8	61

#	ARTICLE	IF	CITATIONS
163	Melphalan versus melphalan plus busulphan in conditioning to autologous stem cell transplantation for low-risk multiple myeloma. <i>The Hematology Journal</i> , 2004, 5, 118-122.	2.0	30
164	Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. <i>British Journal of Haematology</i> , 2004, 126, 475-486.	1.2	90
165	Crosstalk between angiogenesis and lymphangiogenesis in tumor progression. <i>Leukemia</i> , 2004, 18, 1054-1058.	3.3	76
166	Human CD4 mimicry by anti-idiotypic monoclonal antibody 16D7 is based on a conformational epitope. <i>Immunology Letters</i> , 2004, 95, 145-153.	1.1	3
167	Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection. <i>European Journal of Immunology</i> , 2004, 34, 126-136.	1.6	97
168	Osteoclast-like Cell Formation by Circulating Myeloma B Lymphocytes: Role of RANK-L. <i>Leukemia and Lymphoma</i> , 2004, 45, 377-380.	0.6	16
169	Genetic and epigenetic mechanisms of multiple myeloma. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 357-364.	0.8	1
170	CXCR3-binding chemokines in multiple myeloma. <i>Cancer Letters</i> , 2004, 207, 221-227.	3.2	50
171	Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy. <i>Cancer Letters</i> , 2004, 216, 103-107.	3.2	24
172	VEGF and Tumor Progression in Human Melanoma. , 2004, , 48-53.		1
173	Recent Advances in Understanding the Pathogenesis of Anemia in Multiple Myeloma. <i>International Journal of Hematology</i> , 2003, 78, 121-125.	0.7	21
174	Size variants of beta-2-microglobulin-free human leucocyte antigen class I heavy chain make different contributions to its serum increase in multiple myeloma. <i>British Journal of Haematology</i> , 2003, 120, 36-43.	1.2	4
175	Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. <i>British Journal of Haematology</i> , 2003, 122, 39-52.	1.2	65
176	Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia. <i>Clinical and Experimental Immunology</i> , 2003, 133, 275-282.	1.1	80
177	Tryptase-positive mast cells correlate positively with bone marrow angiogenesis in B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2003, 17, 1428-1430.	3.3	71
178	Vascular endothelial growth factor and its receptors in multiple myeloma. <i>Leukemia</i> , 2003, 17, 1961-1966.	3.3	74
179	Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-I) in active lupus. <i>Lupus</i> , 2003, 12, 8-14.	0.8	31
180	Angiogenesis and Anti-Angiogenesis in Hematological Malignancies. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2003, 12, 11-22.	1.8	27

#	ARTICLE	IF	CITATIONS
181	Î²2-Microglobulin-Free HLA Class I Heavy Chain Epitope Mimicry by Monoclonal Antibody HC-10-Specific Peptide. <i>Journal of Immunology</i> , 2003, 171, 1918-1926.	0.4	150
182	Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon Î± with an anti-CD20. <i>Blood</i> , 2003, 101, 3818-3826.	0.6	361
183	Endothelial cells in the bone marrow of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3340-3348.	0.6	173
184	A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. <i>Haematologica</i> , 2003, 88, 176-85.	1.7	93
185	Anemia in Multiple Myeloma: Role of Deregulated Plasma Cell Apoptosis. <i>Leukemia and Lymphoma</i> , 2002, 43, 1527-1533.	0.6	10
186	Negative regulation of erythroblast maturation by Fas-L+/TRAIL+ highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. <i>Blood</i> , 2002, 99, 1305-1313.	0.6	97
187	Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002, 100, 3344-3351.	0.6	120
188	IN SITU HYBRIDIZATION AND IMMUNOGOLD LOCALIZATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2 ON THE PERICYTES OF THE CHICK CHORIOALLANTOIC MEMBRANE. <i>Cytokine</i> , 2002, 17, 262-265.	1.4	10
189	Endothelial Cell Heterogeneity and Organ Specificity. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 81-90.	1.8	137
190	Docetaxel Versus Paclitaxel for Antiangiogenesis. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 103-118.	1.8	119
191	Mast Cell Heterogeneity in B-cell Non-Hodgkin's Lymphomas: An Ultrastructural Study. <i>Leukemia and Lymphoma</i> , 2002, 43, 2201-2205.	0.6	19
192	Correlation of bone marrow angiogenesis and mast cells with tryptase activity in myelodysplastic syndromes. <i>Leukemia</i> , 2002, 16, 1680-1684.	3.3	73
193	Assessment of safety and the immune response to the CD4 "internal antigen" mouse anti-idiotypic Mab 16D7 in four patients with SLE. <i>Journal of Clinical Immunology</i> , 2002, 22, 13-22.	2.0	5
194	Cross-talk Between Hematopoiesis and Angiogenesis Signaling Pathways. <i>Current Molecular Medicine</i> , 2002, 2, 537-543.	0.6	32
195	Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple myeloma. <i>Haematologica</i> , 2002, 87, 836-45.	1.7	63
196	The role of recombinant human erythropoietin alpha in the treatment of chronic anemia in multiple myeloma. <i>Reviews in Clinical and Experimental Hematology</i> , 2002, Suppl 1, 32-8.	0.1	0
197	Postnatal vasculogenesis. <i>Mechanisms of Development</i> , 2001, 100, 157-163.	1.7	128
198	Autocrine interleukin-6 production and highly malignant multiple myeloma: relation with resistance to drug-induced apoptosis. <i>Blood</i> , 2001, 97, 483-489.	0.6	149

#	ARTICLE	IF	CITATIONS
199	Fas-L up-regulation by highly malignant myeloma plasma cells: role in the pathogenesis of anemia and disease progression. <i>Blood</i> , 2001, 97, 1155-1164.	0.6	51
200	Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 172-179.	1.2	167
201	Microvessel overexpression of aquaporin 1 parallels bone marrow angiogenesis in patients with active multiple myeloma. <i>British Journal of Haematology</i> , 2001, 113, 415-421.	1.2	97
202	The role of mast cells in tumour angiogenesis. <i>British Journal of Haematology</i> , 2001, 115, 514-521.	1.2	126
203	Mast cells and their secretory granules are angiogenic in the chick embryo chorioallantoic membrane. <i>Clinical and Experimental Allergy</i> , 2001, 31, 602-608.	1.4	71
204	Deregulated cytokine network and defective Th1 immune response in multiple myeloma. <i>Clinical and Experimental Immunology</i> , 2001, 125, 190-197.	1.1	71
205	The cryoglobulins: an overview. <i>European Journal of Clinical Investigation</i> , 2001, 31, 628-638.	1.7	199
206	$\alpha_5\beta_1$ integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. <i>Experimental Hematology</i> , 2001, 29, 993-1003.	0.2	76
207	Role of Hematopoietic Growth Factors in Angiogenesis. <i>Acta Haematologica</i> , 2001, 106, 157-161.	0.7	10
208	Coordinate immunoreactivity to vascular endothelial growth factor receptor-2 and its ligand suggests a paracrine regulation during the development of the vascular system in the chick embryo bursa of Fabricius. <i>International Journal of Molecular Medicine</i> , 2001, 7, 365-8.	1.8	1
209	Molecular Characterization of B Cell Clonal Expansions in the Liver of Chronically Hepatitis C Virus-Infected Patients. <i>Journal of Immunology</i> , 2001, 167, 21-29.	0.4	109
210	Anti-Fas (CD95/Apo-I) Autoantibodies and Soluble Fas Levels Concur in T Cell Depletion in HIV Type 1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 603-614.	0.5	4
211	Bone marrow angiogenesis in patients with active multiple myeloma. <i>Seminars in Oncology</i> , 2001, 28, 543-550.	0.8	58
212	The Chick Embryo Chorioallantoic Membrane as a Model for in vivo Research on Anti-Angiogenesis. <i>Current Pharmaceutical Biotechnology</i> , 2000, 1, 73-82.	0.9	106
213	Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 171-175.	2.3	82
214	Gastric mucosa as an additional extrahepatic localization of hepatitis C virus: Viral detection in gastric low-grade lymphoma associated with autoimmune disease and in chronic gastritis. <i>Hepatology</i> , 2000, 31, 182-189.	3.6	83
215	An experimental study in the chick embryo chorioallantoic membrane of the anti-angiogenic activity of cyclosporine in rheumatoid arthritis versus osteoarthritis. <i>Inflammation Research</i> , 2000, 49, 418-423.	1.6	12
216	Cyclosporine-A plus steroids versus steroids alone in the 12-month treatment of systemic lupus erythematosus. <i>International Journal of Clinical and Laboratory Research</i> , 2000, 30, 67-73.	1.0	35

#	ARTICLE	IF	CITATIONS
217	Angiogenesis and mast cell density with tryptase activity increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>International Journal of Cancer</i> , 2000, 85, 171-175.	2.3	128
218	Immunogenicity of an Eight Amino Acid Domain Shared by Fas (CD95/Apo-I) and HIV-1 gp120. I. Structural and Antigenic Analysis. <i>Molecular Medicine</i> , 2000, 6, 494-508.	1.9	4
219	VEINCTR-N, an Immunogenic Epitope of Fas (CD95/Apo-I), and Soluble Fas Enhance T-cell Apoptosis in vitro. II. Functional Analysis and Possible Implications in HIV-1 Disease. <i>Molecular Medicine</i> , 2000, 6, 509-526.	1.9	8
220	State-of-the-Art Review: Hematopoiesis and Angiogenesis: A Link Between Two Apparently Independent Processes. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000, 9, 13-19.	1.8	26
221	The Lymphoid System in Hepatitis C Virus Infection: Autoimmunity, Mixed Cryoglobulinemia, and Overt B-Cell Malignancy. <i>Seminars in Liver Disease</i> , 2000, 20, 143-158.	1.8	144
222	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. <i>Blood</i> , 1999, 93, 3064-3073.	0.6	537
223	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. <i>Blood</i> , 1999, 94, 4143-4155.	0.6	259
224	Increased serum levels of beta2m-free HLA class I heavy chain in multiple myeloma. <i>British Journal of Haematology</i> , 1999, 106, 987-994.	1.2	14
225	Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. <i>British Journal of Cancer</i> , 1999, 79, 965-970.	2.9	130
226	The Role of the Vascular Phase in Solid Tumor Growth: A Historical Review. <i>Neoplasia</i> , 1999, 1, 293-302.	2.3	137
227	Serum levels of beta-2-microglobulin-free heavy chain of HLA class I antigen in healthy individuals: relationship to their class I allotype. <i>Human Immunology</i> , 1999, 60, 1058-1066.	1.2	8
228	Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. <i>British Journal of Cancer</i> , 1999, 79, 451-455.	2.9	240
229	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>Blood</i> , 1999, 93, 2627-2636.	0.6	461
230	Human Erythropoietin Induces a Pro-Angiogenic Phenotype in Cultured Endothelial Cells and Stimulates Neovascularization In Vivo. <i>Blood</i> , 1999, 93, 2627-2636.	0.6	16
231	Bone Marrow Neovascularization, Plasma Cell Angiogenic Potential, and Matrix Metalloproteinase-2 Secretion Parallel Progression of Human Multiple Myeloma. <i>Blood</i> , 1999, 93, 3064-3073.	0.6	119
232	Antiangiogenesis Is Produced by Nontoxic Doses of Vinblastine. <i>Blood</i> , 1999, 94, 4143-4155.	0.6	17
233	Human lymphoblastoid cells produce extracellular matrix-degrading enzymes and induce endothelial cell proliferation, migration, morphogenesis, and angiogenesis. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 55-68.	1.0	85
234	The effectiveness and tolerability of epoetin alfa in patients with multiple myeloma refractory to chemotherapy. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 127-134.	1.0	48

#	ARTICLE	IF	CITATIONS
235	Evaluation of biotinylated cells as a source of antigens for characterization of their molecular profile. <i>International Journal of Clinical and Laboratory Research</i> , 1998, 28, 246-251.	1.0	3
236	Do mast cells help to induce angiogenesis in B-cell non-Hodgkin's lymphomas?. <i>British Journal of Cancer</i> , 1998, 77, 1900-1906.	2.9	78
237	Hepatitis C Virus Infection, Mixed Cryoglobulinemia, and Non-Hodgkin's Lymphoma: an Emerging Picture. <i>Leukemia and Lymphoma</i> , 1998, 31, 463-476.	0.6	66
238	Hepatitis C Virus Infection Involves CD34+Hematopoietic Progenitor Cells in Hepatitis C Virus Chronic Carriers. <i>Blood</i> , 1998, 92, 3328-3337.	0.6	82
239	Hepatitis C Virus Infection Involves CD34+Hematopoietic Progenitor Cells in Hepatitis C Virus Chronic Carriers. <i>Blood</i> , 1998, 92, 3328-3337.	0.6	22
240	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. <i>Blood</i> , 1997, 90, 776-782.	0.6	217
241	The Fab region of IgG2 human myeloma proteins does not bear the streptococcal protein G-specific determinant. <i>Journal of Immunological Methods</i> , 1997, 203, 153-155.	0.6	7
242	A letter from the editor. <i>International Journal of Clinical and Laboratory Research</i> , 1997, 27, 1-1.	1.0	0
243	IgG M-components in active myeloma patients induce a down-regulation of natural killer cell activity. <i>International Journal of Clinical and Laboratory Research</i> , 1997, 27, 48-54.	1.0	32
244	Mixed cryoglobulinemia as a model of systemic vasculitis. <i>Clinical Reviews in Allergy and Immunology</i> , 1997, 15, 97-119.	2.9	38
245	Absence of streptococcal protein G (PG)-specific determinant in the Fab region of human IgG2. <i>Clinical and Experimental Immunology</i> , 1997, 109, 272-278.	1.1	4
246	Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. <i>Hepatology</i> , 1997, 25, 1237-1244.	3.6	155
247	In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma. <i>Cancer</i> , 1997, 80, 22-33.	2.0	39
248	Characterization of Overt B-Cell Lymphomas in Patients With Hepatitis C Virus Infection. <i>Blood</i> , 1997, 90, 776-782.	0.6	23
249	Anti-Idiotypic Monoclonal Antibody (mAb) to Anti-CD4 mAb as Surrogate of Human CD4 Antigen (Ag) for Active Immunotherapy of Autoimmune Diseases. , 1997, , 239-254.		0
250	Intravenous immune globulin therapy of lupus nephritis: use of pathogenic anti-DNA-reactive IgG. <i>Clinical and Experimental Immunology</i> , 1996, 104, 91-97.	1.1	37
251	Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. <i>Aids</i> , 1996, 10, 131-141.	1.0	94
252	Immunochemical and biomolecular studies of circulating immune complexes isolated from patients with acute and chronic hepatitis C virus infection. <i>European Journal of Clinical Investigation</i> , 1996, 26, 465-475.	1.7	34

#	ARTICLE	IF	CITATIONS
253	Cross-linking of Fas By Antibodies to a Peculiar Domain of gp120 V3 Loop Can Enhance T Cell Apoptosis in HIV-1â€“infected Patients. <i>Journal of Experimental Medicine</i> , 1996, 184, 2287-2300.	4.2	26
254	Expression of Tenascin is Related to Histologic Malignancy and Angiogenesis in B-Cell non-Hodgkin's Lymphomas. <i>Leukemia and Lymphoma</i> , 1996, 22, 473-481.	0.6	35
255	HCV-Induced Cryoglobulinemic Vasculitis: Pathogenesis and Therapeutic Implications. , 1996, , 260-272.		0
256	Bone marrow of patients with active multiple myeloma: Angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. <i>American Journal of Hematology</i> , 1995, 50, 9-14.	2.0	131
257	Localization of hepatitis C virus antigens in liver and skin tissues of chronic hepatitis C virusâ€“infected patients with mixed cryoglobulinemia. <i>Hepatology</i> , 1995, 21, 305-312.	3.6	110
258	Immunomodulation of T and B cell functions in multiple myeloma patients treated with combined erythropoietin and Î±-interferon therapy. <i>International Journal of Clinical and Laboratory Research</i> , 1995, 25, 79-83.	1.0	9
259	Demonstration and Distribution of HCV RNA Sequences by in situ Hybridization and HCV-Related Proteins by Immunohistochemistry in the Liver Tissue of Patients with Chronic HCV Infection. <i>Pathobiology</i> , 1995, 63, 239-248.	1.9	14
260	Angiogenesis in B Cell Lymphoproliferative Diseases. <i>Biological and Clinical Studies. Leukemia and Lymphoma</i> , 1995, 20, 27-38.	0.6	94
261	Human CD4 â€œinternal antigenâ€œ-mimicry by anti-idiotypic monoclonal antibodies. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 33-40.	1.0	9
262	Anti-idiotypic monoclonal antibodies (mAb) to an anti-CD4 mAb induce CD4+ T cell depletion in rabbit. <i>International Journal of Clinical and Laboratory Research</i> , 1994, 24, 208-212.	1.0	4
263	Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. <i>Cancer</i> , 1994, 74, 1792-1800.	2.0	47
264	Bone marrow angiogenesis and progression in multiple myeloma. <i>British Journal of Haematology</i> , 1994, 87, 503-508.	1.2	580
265	Molecular Specificities of CD4+ T Cell-Reactive IgM in Human Immunodeficiency Virus (HIV-1) Infection. <i>Clinical Immunology and Immunopathology</i> , 1994, 70, 40-46.	2.1	7
266	Differential expression of two ICAMâ€œ1 epitopes and LFAâ€œ1 chains in Bâ€œcell nonâ€œHodgkin's lymphomas. <i>European Journal of Haematology</i> , 1994, 53, 85-92.	1.1	14
267	New Clinical and Molecular Features of â€œEssentialâ€œ-Mixed Cryoglobulinemia. <i>Medical Science Symposia Series</i> , 1994, , 27-36.	0.0	1
268	Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor. <i>Cancer</i> , 1993, 72, 455-461.	2.0	99
269	Hepatitis C virus c100 antigen in liver tissue from patients with acute and chronic infection. <i>Hepatology</i> , 1993, 18, 240-245.	3.6	44
270	Hepatitis C virus infection and mixed cryoglobulinemia: a striking association. <i>International Journal of Clinical and Laboratory Research</i> , 1993, 23, 45-49.	1.0	51

#	ARTICLE	IF	CITATIONS
271	Defibrotide in the treatment of Raynaud's phenomenon in patients with progressive systemic sclerosis or essential mixed cryoglobulinemia. <i>Current Therapeutic Research</i> , 1993, 53, 48-58.	0.5	0
272	Expression and Distribution of a Human Colon-Carcinoma-Associated Antigen in Normal and Diseased Liver Tissue. <i>Pathobiology</i> , 1993, 61, 193-196.	1.9	6
273	Treatment of Hepatitis C Virus-Associated Chronic Liver Disease with α -Interferon and Inosine Pranobex: Combination Schedule vs Monotherapies. , 1993, , 209-215.		0
274	Hepatitis-C-Virus-Related Chronic Liver Disease of Sporadic Type: Clinical, Serological and Histological Features. <i>Digestion</i> , 1992, 51, 115-120.	1.2	5
275	Deflazacort versus Prednisone in the Treatment of Essential Mixed Cryoglobulinemia A Between-Patient Controlled Clinical Study. <i>International Archives of Allergy and Immunology</i> , 1992, 99, 306-310.	0.9	13
276	Circulating levels and liver tissue distribution of intercellular adhesion molecule-1 during α -interferon therapy of hepatitis C virus-associated chronic active liver disease. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 22, 100-105.	1.0	8
277	Immunochemical and functional characterization of anti-idiotypic antibodies to a mouse anti-CD4 monoclonal antibody. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 21, 179-185.	1.0	3
278	A rapid direct microwave irradiation technique for demonstrating hepatitis C virus-associated C100 protein in formalin-fixed liver tissue. <i>International Journal of Clinical and Laboratory Research</i> , 1992, 21, 199-201.	1.0	5
279	Parallelism of serum anti-F(ab ϵ) ₂ and anti-cationic IgG reactivities in patients with systemic lupus erythematosus. <i>Clinical Immunology and Immunopathology</i> , 1991, 59, 256-270.	2.1	4
280	Monoclonal antibodies against human anti-F(ab ϵ) ₂ antibodies react with light chain epitopes. <i>Clinical Immunology and Immunopathology</i> , 1991, 59, 139-155.	2.1	4
281	Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients.. <i>Journal of Clinical Oncology</i> , 1991, 9, 444-448.	0.8	120
282	Kinetics of Anti-Hepatitis C Virus Response during Acute Hepatitis in an Immunosuppressed HCV Chronically Infected Patient. <i>Digestion</i> , 1991, 50, 52-60.	1.2	9
283	Purification of human immunoglobulins by sequential precipitation with caprylic acid and ammonium sulphate. <i>Journal of Immunological Methods</i> , 1990, 128, 9-16.	0.6	107
284	Maintenance Treatment with Recombinant Interferon Alfa-2b in Patients with Multiple Myeloma Responding to Conventional Induction Chemotherapy. <i>New England Journal of Medicine</i> , 1990, 322, 1430-1434.	13.9	374
285	Stimulatin of antibody response in the gastro-intestinal mucosa of immunodeficient mice by oral treatment with bacterial antigens. An immunoperoxidase study. <i>International Journal of Immunopharmacology</i> , 1989, 11, 341-348.	1.1	1
286	ANTIBODIES TO HEPATITIS C VIRUS IN NON-A, NON-B POST-TRANSFUSION AND CRYPTOGENETIC CHRONIC LIVER DISEASE. <i>Lancet, The</i> , 1989, 334, 798-799.	6.3	36
287	HBeAg/Anti-HBe circulating immune complexes in patients chronically infected with hepatitis B virus. <i>Research in Clinic and Laboratory</i> , 1989, 19, 81-91.	0.3	1
288	In vitro inhibition of anti-DNA producing cells from systemic lupus erythematosus patients by autologous anti-F(ab ϵ) ₂ antibodies. <i>Clinical Immunology and Immunopathology</i> , 1987, 42, 50-62.	2.1	17

#	ARTICLE	IF	CITATIONS
289	Treatment of multiple myeloma: A randomized study of three different regimens. <i>Leukemia Research</i> , 1985, 9, 1043-1049.	0.4	20
290	Analbuminemia: Report of a Case and Review of the Literature ¹ . <i>Vox Sanguinis</i> , 1980, 39, 153-161.	0.7	40
291	A New Case of Mu Heavy Chain Disease: Clinical and Immunochemical Studies. <i>Blood</i> , 1974, 43, 713-719.	0.6	29
292	Antibody Deficiency in Paraproteinemia. <i>Acta Medica Scandinavica</i> , 1966, 179, 755-768.	0.0	22